NanoViricides, Inc. (NNVC) Covered Calls

NanoViricides, Inc. covered calls NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States.

You can sell covered calls on NanoViricides, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NNVC (prices last updated Fri 4:16 PM ET):

NanoViricides, Inc. (NNVC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.23 -0.11 1.21 1.28 201K - 0.0
Covered Calls For NanoViricides, Inc. (NNVC)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 2.5 0.00 1.28 0.0% 0.0%
Jan 17 2.5 0.00 1.28 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

NanoViricides, Inc. is a development stage company, which is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. The company has six drug development programs, such as Oral FluCide against all Influenzas, A Piggy-back version of Flucide for hospitalized patients, nanoviricide eye drops against adenoviral EKC and herpes keratitis, HIVCide-I against HIV/AIDS, HerpeCide-I skin cream formulation for herpes cold sores and genital warts, and DengueCide, is designed to attack all types of dengue viruses effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome. NanoViricides was founded by Anil R. Diwan on July 25, 2000 and is headquartered in Shelton, CT.